Low vitamin D use in patients on enzyme-inducing antiseizure drugs raises concerns
Enzyme-inducing antiseizure drugs (ASDs) are associated with increased odds of incident osteoporosis or osteopenia, but vitamin D supplementation is underutilized, according to a study presented at the annual meeting of the American Neurological Association, held from Oct. 17 to 20 in San Diego.
A study presented at the American Neurological Association conference highlights concerns over low vitamin D use in patients on enzyme-inducing antiseizure drugs (ASDs). These drugs have been linked to an increased risk of osteoporosis or osteopenia, but vitamin D supplementation is underutilized, according to Dr. Mehreen Ali from Carle Illinois College of Medicine.
The research used data from the All of Us Research Program, comparing 1,395 adults on enzyme-inducing ASDs to 15,374 adults on non-enzyme-inducing ASDs. The findings showed that enzyme-inducing ASD use was independently associated with a higher odds of incident osteoporosis or osteopenia, even after adjusting for various factors such as age, sex, corticosteroid use, chronic kidney disease, obesity, and vitamin D supplementation.
Interestingly, only 20.7% of patients on enzyme-inducing ASDs received vitamin D supplementation postdiagnosis, compared to 16.2% of patients on non-enzyme-inducing ASDs. This discrepancy suggests a significant gap between guidelines and clinical practices, with vitamin D supplementation being a crucial factor in preventing bone disease.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
